He favors requiring that prospective genericbiologic manufacturers test their drugs in humans before approval . hatch also supports establishing patient registries to track sideeffects that may not occur until years after patients start using aproduct 他认为生物药品仿制企业应该于获批之前在人类身上试验其产品，他还赞同建立病人登记制度以跟踪调查病人用药一年或几年后的才发现的副作用。
